avbryt
Viser resultater for 
Søk heller etter 
Mente du: 
avbryt
Viser resultater for 
Søk heller etter 
Mente du: 

Wilson Therapeutics has completed a SEK 244 million private placement

Moderator

DNB Markets acted as Joint Bookrunner in connection with Wilson Therapeutics' (Nasdaq Stockholm; WTX) SEK 244 million private placement.

 

The private placement launched after close of trading Thursday 7 December and was conducted as an accelerated book-building. Strong demand was generated from reputable institutions and sector specialist funds, both internationally and in Sweden.

 

Wilson Therapeutics is a biopharmaceutical company that develops novel therapies for patients with rare copper-mediated disorders. Its lead product, WTX101, is a first-in-class drug with potential to address the significant unmet medical needs in Wilson Disease.

 

The company will present at DNB’s 8th Annual Healthcare Conference, which will be held on December 1...